Results 111 to 120 of about 19,412 (203)

Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

BMC Medicine
Background Osimertinib has become standard care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients whereas drug resistance remains inevitable.
Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Sha Zhao, Yijun Jia, Xiaozhen Liu, Yiwei Liu, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou   +10 more
doaj   +1 more source

Osimertinib Cost Minimization in Non\u2010Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat

Pharmacokinetic boosting can be a strategy to enhance osimertinib exposure and reduce treatment associated costs. The OSIBOOST trial demonstrated that it was feasible to boost low osimertinib plasma trough levels with cobicistat.
Stevens, Jasper, Oude Munnink, T. H.; id_orcid, Kruithof, Paul, Touw, Daan; id_orcid, van Geel, Robin M. J. M., Touw, Daan J., Kosterink, Jos G. W., Westra, Niels, Oude Munnink, Thijs H., Kruithof, Paul D.; id_orcid, Munnink, Thijs H. Oude, Mian, Paola, van Geel, Robin, Hendriks, Lizza, Hendriks, Lizza E. L., Kosterink, Jos G. W.; id_orcid, Stevens, Jasper; id_orcid, Westra, Niels; id_orcid, Kruithof, Paul D., Croes, Sander   +19 more
core   +1 more source

Understanding Postmarketing Requirements and Commitments for CYP3A‐Mediated Drug–Drug Interactions: An Analysis of FDA‐Approved Drugs From 2015 to 2024

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Jingjing Yu, Ichiko Petrie, Sophie Argon, Katie Owens, Isabelle Ragueneau‐Majlessi   +4 more
wiley   +1 more source

Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study

Background Previous studies have shown that anlotinib plus third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) overcome acquired resistance to EGFR‐TKIs in patients with advanced EGFR‐mutant nonsmall cell lung cancer (
Jinghao Liu, Jun Chen, Xin Li, Yanan Wang, Hongyu Liu, Yongwen Li, Hongbing Zhang, Zihe Zhang, Sen Wei, Boshi Li, Yu Hua, Minghui Liu   +11 more
core   +1 more source

Osimertinib‐induced erythromelalgia: A case report [PDF]

The present study reports a case of osimertinib-induced erythromelalgia in a patient with metastatic lung adenocarcinoma. Osimertinib is an antineoplastic drug that irreversibly inhibits the epidermal growth factor receptor (EGFR) pathway by binding to ...
Alessia Guidotti, Alessia, Bolzon, Anna, Alaibac, Mauro Alessandro   +2 more
core   +1 more source

Restoration of Osimertinib sensitivity in lung cancer through BRD4 inhibitor-mediated depalmitoylation of mutant EGFR via APT1

npj Precision Oncology
Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations initially responds to the third-generation EGFR-tyrosine kinase inhibitor (TKI) Osimertinib.
Wolong Zhou, Shaoqiang Wang, Zhenyu Zhang, Linfeng Li, Jiebo Zhu, Hang Lin, Heng Zhang   +6 more
doaj   +1 more source

Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study

JTO Clinical and Research Reports
Introduction: EGFR tyrosine kinase inhibitors have been the standard treatment for patients with NSCLC who have sensitive EGFR mutations. This study revealed final analysis survival data, biomarkers, and resistance mechanisms of osimertinib plus ...
Hirotsugu Kenmotsu, MD, PhD, Kazuko Sakai, PhD, Keita Mori, PhD, Terufumi Kato, MD, Shunichi Sugawara, MD, PhD, Keisuke Kirita, MD, PhD, Yasuto Yoneshima, MD, PhD, Koichi Azuma, MD, PhD, Kazumi Nishino, MD, PhD, Shunsuke Teraoka, MD, Ryo Koyama, MD, PhD, Ken Masuda, MD, PhD, Hidetoshi Hayashi, MD, PhD, Ryo Toyozawa, MD, PhD, Satoru Miura, MD, PhD, Yuki Sato, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuto Nishio, MD, PhD, Toshiaki Takahashi, MD, PhD   +19 more
doaj   +1 more source

Early stage non–small cell lung cancer: Toward a risk‐adaptive paradigm in the era of biologic precision

CA: A Cancer Journal for Clinicians, Volume 76, Issue 5, September/October 2026.
Abstract The clinical landscape of early stage non–small cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low‐dose computed tomography screening, the frequent detection of ground‐glass opacities, and a rising incidence among never‐smokers, the diagnostic center of gravity has shifted toward earlier, potentially ...
Chaoqi Zhang, Xuanyu Gu, Pan Wang, Dongyu Li, Guochao Zhang, Ting Wang, Peng Wu, Wei Rao, Shan Muhammad, Binghua Tan, Yun Che, Mobai Zhu, Qilin Qiao, Fanbo Lai, Bohui Zhao, Kailun Fei, Yue Wu, Zhihui Zhang, Min Dai, Wanqing Chen, Yawei Zhang, Nan Bi, Jie Wang, Jie He   +23 more
wiley   +1 more source

The N6-methyladenosine-mediated cLMNB1 degrades FGFR4 to overcome osimertinib resistance in non-small cell lung cancer

Cell Death and Disease
Osimertinib resistance is the main challenge in treating EGFR-mutant lung adenocarcinoma (LUAD). The role of N6-methyladenosine (m6A) modification of circular RNAs (circRNAs) in osimertinib-resistant LUAD remains largely unknown.
Yuxian Qian, Hui Wang, Yipeng Feng, Yijian Zhang, Qianfan Hu, Zehao Pan, Xiaodong Zhang, Lin Xu, Li Yin, Gaochao Dong, Xing Zhang, Feng Jiang   +11 more
doaj   +1 more source

A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition

Guanming Jiang,1,* Xuyi Liu,2,3,* Dou Zhang,2,3,* Zhenying Diao,2,3 Xiaojun Yang,1 Qinquan Tan,1 Shiyuan Chen,1 Wan Zhang,1 Xiumao Yin,1 Ting Yin,2,3 Xiaozhen Wang,4 Jianping Zhou5 1Department of Oncology, Tenth Affiliated ...
Liu X, Yang X, Zhang W, Yin X, Zhang D, Diao Z, Yin T, Jiang G, Wang X, Chen S, Tan Q, Zhou J   +11 more
core